Brachytherapy for prostate cancer: A systematic review

Advances in Urology

Volumn , Issue , 2009, Pages

  Koukourakis, Georgios ^a   Kelekis, Nikolaos ^a   Armonis, Vassilios ^b   Kouloulias, Vassilios ^a  

^a Second Department of Radiology   (Greece)

^b Pathology Dep 6th IKA Hospital Athens   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349197791     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2009/327945     Document Type: Article

References (76)

1. Scardino P., Update: NCCN prostate cancer clinical practice guidelines Journal of the National Comprehensive Cancer Network 2005 3 supplement 1 29 33
2. Thompson I., Thrasher B. J., Aus G., Guideline for the management of clinically localized prostate cancer The Journal of Urology 2007 177 6 2106 2131 (Pubitemid 46726449)
3. Galalae M. R., Martinez A., Nuernberg N., Hypofractionated conformal HDR brachytherapy in hormone naove men with localized prostate cancer: is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlenther Onkologie 2006 182 3 135 141
4. Pisansky M. T., External-beam radiotherapy for localized prostate cancer The New England Journal of Medicine 2006 355 15 1583 1591
5. Zelefsky M. J., Kuban D. A., Levy L. B., Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation International Journal of Radiation Oncology Biology Physics 2007 67 2 327 333
6. International Commission on Radiation Units and Measurements (ICRU), Dose and volume specification for reporting intracavitary therapy in gynecology 1985 38 Bethesda, Md, USA International Commission on Radiation Units and Measurements
7. Stone N. N., Hong S., Lo Y. C., Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy Brachytherapy 2003 2 17 25
8. Stock R. G., Stone N. N., Dahlal M., What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms Brachytherapy 2002 1 83 89
9. Stone N. N., Roy J., Hong S., Prostate gland motion and deformation caused by needle placement during brachytherapy Brachytherapy 2002 1 154 160
10. McNeely L. K., Stone N. N., Presser J., Influence of prostate volume on dosimetry results in real-time 125I seed implantation International Journal of Radiation Oncology, Biology, Physics 2004 58 292 299
11. Stock R. G., Stone N. N., Importance of post-implant dosimetry in permanent prostate brachytherapy European Urology 2002 41 434 439
12. VanDyk S., Bernshaw D. L., Nag S., Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society International Journal of Radiation Oncology, Biology, Physics 2001 51 1422 1430
13. Stock R. G., Stone N. N., Lo Y. C., Postimplant dosimetry for 125I prostate implants: definitions and factors affecting outcome International Journal of Radiation Oncology Biology Physics 2000 48 899 906
14. Stock R. G., Cesaretti J. A., Stone N. N., Disease-specific survival following the brachytherapy management of prostate cancer International Journal of Radiation Oncology Biology Physics 2006 64 810 816
15. Ho A. Y., Burri R. J., Jennings G. T., Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer Brachytherapy 2007 6 38 43
16. Stock R. G., Lo Y. C., Gaildon M., Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined Pd-103 prostate implantation and external beam irradiation International Journal of Radiation Oncology Biology Physics 1999 45 385 389
17. Blasko J. C., Ragde H., Schumacher D., Transperineal percutaneous iodine- 125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance Endocuriether Hypertherm Oncology 1987 3 131 139
18. Ragde H., Blasko J. C., Schumacher D., Use of transrectal ultrasound in transperineal iodine-125 seeding for prostate cancer Journal of Endourology and Methodology 1989 3 209 218
19. Blasko J. C., Grimm P., Ragde H., Brachytherapy and organ preservation in the management of carcinoma of the prostate Seminars in Radiation Oncology 1993 3 240 249
20. Grimm P. D., Blasko J. C., Sylvester J. E., Technical improvement in permanent seed implantation: a two-stage brachytherapy systemml: description and comparison with current technique Brachytherapy 2004 3 34 40
21. Ellis R. J., Zhou H., Kim E. Y., Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide Brachytherapy 2007 6 1 16 25
22. Zelefsky M. J., Yamada Y., Cohen G. N., Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer International Journal of Radiation Oncology, Biology, Physics 2007 67 65 70
23. Zelefsky M. J., Kuban D. A., Levy L. B., Multi-institutional analysis of long-term outcome for stages T1T2 prostate cancer treated with permanent seed implantation International Journal of Radiation Oncology, Biology, Physics 2007 67 327 333
24. Block T., Czempiel H., Zimmermann F., Transperineal permanent seed implantation of low-risk prostate cancer: 5-year-experiences in 118 patients Strahlenther Onkologie 2006 182 666 671
25. Khaksar S. J., Laing R. W., Henderson A., Biochemical (prostatespecific antigen) relapse-free survival and toxicity after 125I low-doserate prostate brachytherapy BJU International 2006 98 1210 1215
26. Guedea F., Aguilo F., Polo A., Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1T2 prostate cancer Radiotherapy and Oncology 2006 57 61
27. Prada P. J., Hevia M., Juan G., I125 low dose rate brachytherapy in localized prostate cancer: preliminary results after 5 years Archivos Espanoles de Urologia 2005 58 213 226
28. Potters L., Morgenstern C., Calugaru E., 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer The Journal of Urology 2005 173 1562 1566
29. Sharkey J., Cantor A., Solc Z., 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice Brachytherapy 2005 4 34 44
30. Joseph J., Al-Qaisieh B., Ash D., Prostate-specific antigen relapsefree survival in patients with localized prostate cancer treated by brachytherapy BJU International 2004 94 1235 1238
31. Critz F. A., Levinson K., 10-year disease-free survival rates after simultaneousirradiation for prostate cancer with a focus on calculation methodology The Journal of Urology 2004 172 6, part 1 2232 2238
32. Bladou F., Salem N., Simonian-Sauve M., Permanent iodine 125 implant brachytherapy in localized prostate cancer: results of the first 4 years of experience Prognostic Urology 2004 14 345 352
33. Battermann J. J., Boon T. A., Moerland M. A., Results of permanent prostate brachytherapy, 13 years of experience at a single institution Radiotherapy and Oncology 2004 71 23 28
34. Damico A. V., Tempany C. M., Schultz D., Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate Urology 2003 62 1063 1067
35. Sylvester J. E., Blasko J. C., Grimm P. D., Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience International Journal of Radiation Oncology, Biology, Physics 2003 57 944 952
36. Kwok Y., DiBiase S. J., Amin P. P., Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy International Journal of Radiation Oncology Biology Physics 2001 53 588 594
37. Grimm P. D., Blasko J. C., Sylvester J. E., 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy International Journal of Radiation Oncology Biology Physics 2001 51 31 40
38. Wallner K., Merrick G., True L., 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial International Journal of Radiation Oncology Biology Physics 2003 57 1297 1303
39. Martin A. G., Roy J., Beaulieu L., Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithmml: a 12-year Canadian experience International Journal of Radiation Oncology Biology Physics 2007 67 2 334 341
40. Merrick G. S., Butler W. M., Wallner K. E., The impact of primary gleason grade on biochemical outcome following brachytherapy for hormone-naive gleason score 7 prostate cancer Cancer Journal 2005 11 3 234 240
41. Koutrouvelis P. G., Gillenwater J., Lailas N., High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8-year follow-up Radiotherapy and Oncology 2003 67 3 303 308
42. Stock R. G., Stone N. N., Tabert A., A dose-response study for I-125 prostate implants International Journal of Radiation Oncology Biology Physics 1998 41 1 101 108
43. Stock R. G., Ho A., Cesaretti J. A., Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control International Journal of Radiation Oncology Biology Physics 2006 66 2 389 394
44. Dattoli M., Wallner K., True L., Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension Urology 2007 69 2 334 337
45. Merrick G. S., Butler W. M., Wallner K. E., Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam International Journal of Radiation Oncology Biology Physics 2007 68 1 34 40
46. Copp H., Bissonette E. A., Theodorescu D., Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer Urology 2005 65 6 1146 1151
47. Grossfeld G. D., Latini D. M., Lubeck D. P., Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer The Journal of Urology 2003 169 157 163
48. Donohue J. F., Bianco F. J. Jr., Kuroiwa K., Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading Journal of Urology 2006 176 3 991 995
49. Bentzen S. M., Ritter M. A., The / ratio for prostate cancer: what is it, really? Radiotherapy and Oncology 2005 76 1 3
50. Kovcs G., Ptter R., Hammer J., GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer Radiotherapy and Oncology 2005 74 2 137 148
51. Astrm L., Pedersen D., Mercke C., Holmng S., Johansson K. A., Longterm outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer Radiotherapy and Oncology 2005 74 2 157 161
52. Flynn J. P., Kelly D. A., Brookover T., High dose rate (HDR) brachytherapy boost for prostate cancer gives high control rate International Journal of Radiation Oncology Biology Physics 2007 69 3, supplement 1 S323 S324
53. Galalae R. M., Martinez A., Mate T., Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer International Journal of Radiation Oncology Biology Physics 2004 58 4 1048 1055
54. Galalae R. M., Martinez A., Nuernberg N., Hypofractionated conformal HDR brachytherapy in hormone naove men with localized prostate cancer: is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Strahlentherapie and Onkologie 2006 182 3 135 141
55. Guix B., Bartrina J., Henriquez I., Tello J., Vendrell J., Serrate R., Combined treatment 3D-conformal radiotherapy plus HDR brachytherapy as treatment for intermediate- or high-risk prostate cancer: early toxicity and biochemical outcome of a dose-escalation prospective randomized trial International Journal of Radiation Oncology Biology Physics 2007 69 3, supplement 1 S85
56. Izard M. A., Haddad R. L., Fogarty G. B., Rinks A., Dobbins T., Katelaris P., Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer International Journal of Radiation Oncology Biology Physics 2006 66 1 38 47
57. Martinez A., Gonzalez J., Spencer W., Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors Journal of Urology 2003 169 3 974 979
58. Phan T. P., Syed A. M. N., Puthawala A., Sharma A., Khan F., High dose rate brachytherapy as a boost for the treatment of localized prostate cancer Journal of Urology 2007 177 1 123 127
59. Yamada Y., Bhatia S., Zaider M., Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer Brachytherapy 2006 5 3 157 164
60. Demanes D. J., Rodriguez R. R., Schour L., Brandt D., Altieri G., High-doserate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapys 10-year results International Journal of Radiation Oncology Biology Physics 2005 61 5 1306 1316
61. Ghilezan M., Galalae R., Demanes J., 10-Year results in 1577 intermediate/high risk prostate cancer patients treated with external beam RT (EBRT) and hypofractionated high dose rate (HDR) brachytherapy boost International Journal of Radiation Oncology Biology Physics 2007 69 3, supplement 1 S83 S84
62. Hasan Y., Mitchell C., Wilson G., Demanes D. J., Gillian A. A., Martinez A. A., Long-term outcome for high-dose-rate brachytherapy boost treatment of prostate cancer Brachytherapy 2007 6 2 85
63. Demanes D. J., Gilhezan M., Schour L., High dose rate brachytherapy (HDR-BT) as monotherapy for favorable prostate cancer: excellent 5-year control rates and low toxicity International Journal of Radiation Oncology Biology Physics 2007 69 3, supplement 1 S83
64. Ghilezan M., Gustafson G., Vargas C., Kestin L., Martinez A., High-doserate (HDR) brachytherapy (BT) in favorable risk prostate cancer patients is equivalent to low-dose-rate (LDR) BT in terms of 5-year clinical outcome Brachytherapy 2006 5 2 111
65. Grills I. S., Martinez A. A., Hollander M., High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds Journal of Urology 2004 171 3 1098 1104
66. Mark R. J., Akins R. S., Anderson P. J., Interstitial high dose rate (HDR) brachtherapy as monotherapy for early stage prostate cancer: a report of 206 cases International Journal of Radiation Oncology Biology Physics 2007 691 3, supplement 1 S329
67. Rogers L., Hayes J., Childs L., High dose rate brachytherapy as monotherapy for clinically localized prostate cancer International Journal of Radiation Oncology Biology Physics 2005 62 2, supplement 1 616 619
68. Yoshioka Y., Konishi K., Oh R.-J., High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer Radiotherapy and Oncology 2006 80 1 62 68
69. Pisansky T. M., External-beam radiotherapy for localized prostate cancer The New England Journal of Medicine 2006 355 15 1583 1591
70. Kupelian P. A., Potters L., Khuntia D, Radical prostatectomy, external beam radiotherapy 72 Gy, external beam radiotherapy ≥ 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer International Journal of Radiation Oncology Biology Physics 2004 58 1 25 33
71. Deger S., Boehmer D., Trk I., High dose rate brachytherapy of localized prostate cancer European Urology 2002 41 4 420 426
72. Duchesne G. M., Williams S. G., Das R., Tai K. H., Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results Radiotherapy and Oncology 2007 84 2 128 134
73. Martin T., Baltas D., Kurek R., 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer: a pilot study Strahlentherapie und Onkologie 2004 180 4 225 232
74. Zelefsky M. J., Kuban D. A., Levy L. B., Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation International Journal of Radiation Oncology Biology Physics 2007 67 2 327 333
75. Demanes D., Altieri G., Barnaba M., Brandt D., Hill D., Schour L., High dose rate (HDR) monotherapy is equivalent to combined HDR brachytherapy and external beam radiation therapy (EBRT) for early prostate cancer International Journal of Radiation Oncology Biology Physics 2006 66 3, supplement 1 S351
76. White D., Mark R. J., Anderson P. J., Interstitial high dose rate (HDR) brachytherapy + IMRT vs. HDR monotherapy for early stage prostate cancer: a report of 315 cases International Journal of Radiation Oncology Biology Physics 2007 69 3 S363